| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Contribution |
From the Departments of Medicine (Y.W., D.M.R., M.E.A.) and Pharmacology (D.M.R., M.E.A.), Vanderbilt University, Nashville, Tenn.
Correspondence to Mark Anderson, Vanderbilt University Medical Center, 315 Medical Research Building II, Nashville, TN 37232-6300. E-mail mark.anderson{at}mcmail.vanderbilt.edu
| Abstract |
|---|
|
|
|---|
Key Words: calmodulin kinase sarcoplasmic reticulum transient inward current Ca2+-activated chloride current Na+/Ca2+ exchanger
| Introduction |
|---|
|
|
|---|
One mechanism for arrhythmias due to [Ca2+]i overload is activation of a transient inward current (Iti).10 In nonvoltage-clamped cells Iti causes cell membrane depolarization resulting in delayed afterdepolarizations (DADs) and triggered arrhythmias.11 Under near-physiological conditions, Iti may be due to the electrogenic Na+/Ca2+ exchanger operating in forward mode,12 but results of other experiments performed under less physiological conditions (eg, in the absence of extracellular Na+ or after Na+/K+ ATPase inhibition) suggest that this current could also be due to a Ca2+-activated cation nonselective current (ICAN)12 13 14 15 16 or a Ca2+-activated Cl current (ICa/Cl).16 17 18 19
Many conditions such as ischemia and tachycardia20 may be associated with increased [Ca2+]i. Prolongation of action potential repolarization, a therapeutic action of a variety of antiarrhythmic agents,21 is also associated with arrhythmias in cardiomyopathy22 and congenital long-QT syndromes. Whereas the ionic mechanisms underlying action potential prolongation in these settings are becoming better understood, those underlying the accompanying afterdepolarizations and triggered arrhythmias are less well understood. In these studies, we present evidence that the elevated [Ca2+]i, which follows action potential prolongation, can activate Iti due to Na+/Ca2+ exchanger activity and that this activation is dependent on CaM kinase. These results suggest that this CaM kinasedependent mechanism may trigger arrhythmias arising when action potentials are prolonged.
| Materials and Methods |
|---|
|
|
|---|
Solutions
The solutions for preparation of isolated
ventricular myocytes were described
previously.5 The bath solution contained (in mmol/L)
NaCl 140.0, HEPES 5.0, glucose 10.0, KCl 5.4,
CaCl2 2.5, and MgCl2 1.0.
The pH was adjusted to 7.4 with 10 N NaOH. The intracellular solution
contained (in mmol/L) potassium aspartate 120.0, HEPES 5.0, KCl
25.0, disodium ATP 4.0, MgCl2 1.0,
disodium phosphocreatine 2.0, and sodium GTP 2.0. The pH was adjusted
to 7.2 with 1 N KOH. In some experiments, the
Cl current antagonist niflumic
acid23 was added to the bath solution for a final
concentration of 10 to 40 µmol/L. The SR
Ca2+ release channel blocker ryanodine (10
µmol/L) or the sarcoplasmic/endoplasmic reticulum
Ca2+ ATPase antagonist thapsigargin
(1 µmol/L, Calbiochem) were included in other experiments.
Thapsigargin was added as a DMSO stock solution with a final DMSO
concentration of 0.0001 vol %. Unless otherwise noted, all chemicals
were from Sigma.
Electrophysiology
Current Clamp
Cells were stimulated at 0.1 Hz in current clamp mode with 1.0-
to 2.0-nA pulses of depolarizing current (1.25 times threshold) for 3
to 4 ms at room temperature (20°C to 23°C). Action potentials were
low pass filtered at 2 kHz and sampled at 2.5 kHz with a 12-bit analog
to digital converter (Digidata 1200 B) from Axon Instruments.
Representative short (APD50=194
ms; APD90=217 ms) and long
(APD50=422; APD90=561 ms)
action potential waveforms were digitized and stored for application as
voltage commands for most experiments using pClamp 6.03 (Figure 1
).
|
Voltage Clamp
Isolated myocytes were studied with whole-cellmode
voltage-clamp configuration at 32°C on a heated stage (Warner
Instrument Corp) using an amplifier (Axopatch 200B, Axon Instruments),
as previously described.4 5 Micropipette electrode
resistance was 1.5 to 3.5 M
when micropipettes were filled
with the intracellular solution. Membrane currents were low pass
filtered at 2 kHz and sampled at 6.7 kHz. The digitized signals were
stored for later analysis with pClamp 6.03 (Axon Instruments)
and Sigma Plot (Jandel Scientific). Cell membrane capacitance (167±2.2
pF) was measured using the integral of the current transient after a
10-mV hyperpolarizing step from a holding potential of 80 mV or a
10-mV depolarizing step from a holding potential of 0 mV.
Iti Measurement
After a dialysis-and-stabilization period of
5 minutes, cells
were repetitively (
50 times) depolarized at 0.5 Hz with either a long
or a short action potential command waveform (Figure 1
). The
presence or absence of oscillatory currents after completion of
repolarization (Iti) was noted during the
first 50 depolarizations, and peak Iti was
measured as the difference between the current at the onset of the
oscillation and the current at maximum excursion of the
oscillation. Oscillatory currents were also induced at
different test potentials following conventional conditioning steps
(0.5 Hz) from 80 to +10 or +30 mV (Figure 2D
).
|
[Ca2+]i Measurements
Fluo 3
[Ca2+]i was
monitored to compare the effect of long and short action potential
waveforms on [Ca2+]i by
including the pentapotassium salt of the fluorescent
Ca2+ indicator fluo 3 (Molecular Probes) in the
pipette solution (100 µmol/L) as previously described, with
minor modifications.5 Voltage signals were low pass
filtered at 50 Hz before analysis. Steady-state fluo 3
[Ca2+]i transients were
integrated using pClamp 6.03.
Indo 1
The pentapotassium salt of the ratiometric
Ca2+ indicator indo 1 (100 to 300 µmol/L)
was dialyzed into cells to verify a secondary increase in
[Ca2+]i during
Iti. Excitation light was band pass
filtered (360±20 nm) and reflected with a dichroic mirror (375 nm,
Omega Optical) to the myocyte on the inverted microscope stage (Nikon).
Emission light (ie, >375 nm) was reflected through an adjustable
window to exclude extraneous fluorescence, split with a second
dichroic mirror (455 nm), and represented as the ratio of
405±20/500±20 nm. Photobleaching was limited to 10% of peak output
by an electronically controlled shutter device (Uniblitz) for both indo
1 and fluo 3 experiments.
Inhibitory Peptides
In separate experiments, cells were dialyzed for
5 minutes
with inhibitory peptides against CaM kinase, protein kinase
A (PKA), and protein kinase C (PKC) before the experimental protocol
was initiated. CaM kinase was inhibited with the following peptides
(20 µmol/L): 273-302, 291-317, and AC3-I
(KKALHRQEAVDCL).24 The inhibitory peptide
273-302 is modeled after the autoinhibitory region of CaM
kinase and competitively binds to the catalytic site, whereas peptide
291-317 is modeled after the CaM binding region and so competitively
inhibits CaM kinase and other CaM-dependent processes.2 5
The amino acid sequence HRQEAVDC in AC3-I corresponds to the
surrounding autophosphorylation site on CaM kinase,
except that T (Thr286/287) is modified to A (Ala) to prevent
phosphorylation. Thus, AC3-I is a modified CaM kinase
substrate that competitively inhibits (in vitro
IC50,
3 µmol/L) interaction of
activated CaM kinase with substrate.24 Other
serine threonine kinases are not significantly inhibited by AC3-I at
the concentration used in these experiments.24 The peptide
AC3-C (KKALHAQERVDCL) has no inhibitory
activity24 and was included in the pipette solution
(20 µmol/L) in control experiments. CaM kinase
inhibitory peptides were prepared using a solid-phase
peptide synthesizer (Applied Biosystems) and purified by reverse-phase
HPLC. The sequences were confirmed by automated sequencing. These
peptides were generous gifts of Dr Howard Schulman (Stanford
University, Stanford, Calif).
The competitive PKA inhibitory peptide (IC50=0.2 µmol/L) corresponds to positions 6 to 22 of PKA and was included in the pipette solution at 10 µmol/L. The competitive PKC inhibitory peptide (IC50=0.3 µmol/L) corresponds to the autoinhibitory domain positions 19 to 36 of PKC and was included in the pipette solution at 20 µmol/L. Both PKA and PKC inhibitory peptides were obtained commercially (Gibco-BRL). The Na+/Ca2+ exchanger inhibitory peptide (XIP) is modeled after a putative CaM binding site on the Na+/Ca2+ exchanger and acts to potently inhibit Na+/Ca2+ exchanger current in ventricular myocytes when included in the dialysate (10 or 20 µmol/L).25 Scrambled XIP (sXIP) does not affect the Na+/Ca2+ exchanger and was included in the pipette solution (10 µmol/L) for the control experiments.26 Both XIP and sXIP were generous gifts from Dr Kenneth Philipson (UCLA, Los Angeles, Calif).
| Results |
|---|
|
|
|---|
The Transient Inward Current Is Likely Due to the
Na+/Ca2+ Exchanger
Iti was not observed in any (n=6) of
the XIP-treated cells (Figure 2A
), but was present in all
(n=5) cells treated with sXIP (Figure 2B
). In another group of
cells, niflumic acid (n=9) failed to prevent
Iti (Figure 2C
). These experiments
therefore suggest that Iti may be due to
forward-mode Na+/Ca2+
exchange current. When conventional square wave conditioning steps were
used to activate the oscillatory current (Figure 2D
and 2E
), the reversal potential (Erev) was
between +20 and +40 mV (Figure 2F
), which is far different from
the calculated Erev for
Cl (45 mV) or monovalent cations (2 mV)
under these experimental conditions. Treatment with niflumic acid only
significantly inhibited outward current at +40 and +60 mV compared with
control and did not affect inward current or
Erev (Figure 2F
). XIP prevented
inward current oscillations and shifted
Erev in a positive direction (Figure 2F
). The measured Erev for the
oscillatory currents, the lack of effect of niflumic acid, and the
suppression of Iti by XIP are all
consistent with the hypothesis that the predominant mechanism
underlying Iti was the
Na+/Ca2+ exchanger.
The [Ca2+]i Transient Is Greater With the
Long Than the Short Action Potential Waveform
Integrated fluo 3 fluorescence from paired experiments
(Figure 1C
) showed that the steady-state
[Ca2+]i transient with
the long action potential (557±89 Vxms) was significantly greater
than that measured during the short action potential (328±28 Vxms)
waveform (P=0.04, n=5). These results are consistent
with previous reports that show that prolonged action potential
duration is associated with increased
[Ca2+]i27
and suggest that increased
[Ca2+]i is
important for Iti.
The Transient Inward Current Is Associated With Secondary
[Ca2+]i Oscillations
Myocytes dialyzed with indo 1 and exhibiting
Iti (n=3) showed a secondary
[Ca2+]i
oscillation after completion of the long action potential
step. Myocytes without Iti (n=10) did not
have secondary [Ca2+]i
oscillations. Similar observations were made in fluo
3loaded cells. These findings provide further evidence that the
Iti measured in this study is dependent on
an increase in
[Ca2+]i.
The Transient Inward Current Is Dependent on Activator
Ca2+ From the SR
Addition of BAPTA completely inhibited
Iti after stimulation with the long action
potential waveform in 9 of 9 cells studied. Because the release of SR
Ca2+ stores has been linked to
Iti, Iti
inducibility was tested after exposure to ryanodine (n=6) or
thapsigargin (n=6). Iti was not inducible
after exposure to either of these agents. These findings support the
hypothesis that Iti is linked to increased
[Ca2+]i and specifically
indicates that participation of SR activator
Ca2+ is necessary for
Iti after stimulation with a prolonged
action potential waveform.
The Transient Inward Current Is Dependent on CaM Kinase
To test whether CaM kinase is necessary for
Iti, cells were dialyzed with specific CaM
kinase inhibitory peptides. Dialysis with AC3-I (n=11),
273-302 (n=5), or 291-317 (n=4) completely abolished
Iti after stimulation with the prolonged
action waveform (Figure 3
). Dialysis of
the inactive control peptide AC3-C (n=6) had no apparent effect and
failed to inhibit Iti. Like XIP, the CaM
kinase inhibitory peptide AC3-I also inhibited oscillatory
inward currents in response to test potentials from 80 to +20 mV
(Figure 4
) but, unlike XIP (Figure 2F
), AC3-I did not change the
Erev.
|
|
Both PKA and PKC may also participate in
[Ca2+]i
homeostasis.9 28 29 To test for a possible role of these
kinases in Iti development, cells were
dialyzed with suprainhibiting concentrations of protein kinase A
inhibitor (PKI 6-22) (n=6) and PKC 19-36 (n=5), and neither of these
inhibitory peptides prevented
Iti (Figure 3
). These results
suggest that Iti is dependent on CaM and
CaM kinase, but not on PKC or PKA, under these experimental
conditions.
| Discussion |
|---|
|
|
|---|
Action potential prolongation results in increased
[Ca2+]i (Figure 1C
),27 and increased CaM kinase
activity3 4 ; both of these actions have been linked to
EADs.4 28 Iti underlies DADs
and is another cause of arrhythmia due to elevated
[Ca2+]i and oscillatory
release of SR activator
Ca2+.11 32 Because CaM kinase
has recently been shown to enhance SR Ca2+
release during excitation-contraction coupling,1 we
hypothesized that CaM kinase would facilitate
Iti. The present findings show that a
prolonged action potential waveform increases
[Ca2+]i under
steady-state conditions and results in Iti.
Iti measured in response to the prolonged
action potential waveform has dependence on SR activator
Ca2+ similar to that of previously
measured11 32 currents during
[Ca2+]i overload under
near-physiological conditions.
It is increasingly recognized that prolongation of action potential repolarization is an important cause of increased [Ca2+]i27 and that it is associated with lethal arrhythmias in a variety of settings.21 22 Many studies have implicated EADs as an arrhythmogenic trigger when action potential is prolonged. However, most such studies use block of the rapid component of the delayed rectifier (IKr) to prolong action potentials, especially at slow rates.21 Action potential prolongation that persists at fast heart rates is characteristic of blockade of the slow component of the delayed rectifier (IKs), and it is now known that the most common cause of long-QT syndrome is mutations in the KVLQT1 gene, which encodes IKs components.21 Importantly, preliminary reports have implicated DADs as the arrhythmogenic mechanism when IKs is blocked and isoproterenol is added to the experimental preparation.33 The onset of torsade de pointes occurs with adrenergic stress in >95% of patients with mutations in KVLQT1, according to preliminary reports.34 Our findings suggest a possible mechanism for arrhythmias due to action potential prolongation and point out possible proarrhythmic consequences of using IKs blocking agents for antiarrhythmic therapy.
The Identity of the Transient Inward Current
Previous studies have generally concluded that the predominant
inward current after a depolarizing step is due to (forward-mode)
Na+/Ca2+ exchanger current
in the presence of physiological
solutions.12 35 However, other candidate currents include
ICa/Cl and
ICAN.12 13 14 15 16 17 18 19 Our findings
suggest that Iti measured in these
experiments is due to
Na+/Ca2+ exchanger current
for the following reasons. (1) Iti is
inhibited by XIP, but not by the inactive control peptide sXIP (Figure 2
). (2) Erev for the oscillatory
current is approximately +30 mV, which is far different from that
predicted for ICa/Cl (45 mV) or
ICAN (2 mV) but consistent with
previously reported values under similar experimental conditions, in
which both the Na+/Ca2+
exchanger current and ICa/Cl were
present.17 36 (3) Iti
is not inhibited by niflumic acid (Figure 2C
). Niflumic acid did
reduce outward currents at positive potentials (Figure 2F
),
which is consistent with the described outward rectification of
ICa/Cl.19 These results
suggest that Iti is due to the
Na+/Ca2+ exchanger and that
ICa/Cl is present but significant only
at relatively depolarized cell membrane potentials under these
conditions. One recent report in ferret ventricular
myocytes found that the time course for activation of the
Na+/Ca2+ exchanger current
was slower than for ICa/Cl, making
Erev measurement
problematic.37 Limitations to our
conclusion that Iti is due to the
Na+/Ca2+ exchanger in these
experiments are that (1) no antagonists are available to
exclude participation of ICAN, and (2) XIP
is a CaM antagonist over the range of concentrations useful
for inhibition of the
Na+/Ca2+
exchanger.38 Thus, inhibition of
Iti by XIP could occur partially via a CaM
kinasedependent mechanism analogous to the inhibition with the CaM
inhibitory peptide 291-317 (Figure 3D
). It is
interesting to note that XIP shifted the apparent
Erev for the oscillatory current (Figure 2F
), whereas the specific CaM kinase inhibitory
peptide AC3-I did not (Figure 4
), which suggests that XIP
effects are not solely due to CaM kinase inhibition and therefore
likely reflect inhibition of the
Na+/Ca2+ exchanger.
CaM Kinase Inhibition
The specific inhibitory peptides used in these
experiments offer a significant advantage over other organic
inhibitors, because the latter are also
ICa-L
antagonists.1 4 5 Two different peptides
modeled after separate regions of the CaM kinase molecule were
effective at suppressing Iti (Figure 3B
, 3C
, and 4
). A less specific inhibitory peptide
with antagonist actions against CaM (and presumably a
diverse array of CaM-dependent processes, including CaM kinase) was
also effective at preventing Iti (Figure 3D
). Thus, inhibitory peptides acting at 3 different
sites along the CaM kinase activation pathway were all effective in
preventing Iti. In contrast,
inhibitory peptides against PKA or PKC did not prevent
Iti. Although these studies do show that
CaM kinase activity appears necessary for
Iti, the results do not precisely define or
quantify the site(s) of action of CaM kinase inhibition for
Iti suppression. One possibility is that
enhanced [Ca2+]i
activates CaM kinase, which, in turn, augments SR
Ca2+ uptake and release to secondarily
activate Iti caused by forward-mode
Na+/Ca2+ exchange. These
results strongly support the hypothesis that CaM kinase facilitates
Iti due to the
Na+/Ca2+ exchanger during
increased [Ca2+]i. CaM
kinase may thus be a useful antiarrhythmic drug target to prevent
arrhythmias related to
[Ca2+]i overload.
| Acknowledgments |
|---|
Received October 1, 1998; accepted February 1, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. F. Couchonnal and M. E. Anderson The Role of Calmodulin Kinase II in Myocardial Physiology and Disease Physiology, June 1, 2008; 23(3): 151 - 159. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. D. J. ter Keurs and P. A. Boyden Calcium and Arrhythmogenesis Physiol Rev, April 1, 2007; 87(2): 457 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Anderson Multiple downstream proarrhythmic targets for calmodulin kinase II: Moving beyond an ion channel-centric focus Cardiovasc Res, March 1, 2007; 73(4): 657 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, C. Marionneau, R. Zhang, V. Shah, J. W. Hell, J. M. Nerbonne, and M. E. Anderson Calmodulin Kinase II Inhibition Shortens Action Potential Duration by Upregulation of K+ Currents Circ. Res., November 10, 2006; 99(10): 1092 - 1099. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Zaloga, K. A. Harvey, W. Stillwell, and R. Siddiqui Trans Fatty Acids and Coronary Heart Disease Nutr Clin Pract, October 1, 2006; 21(5): 505 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Zaloga, N. Ruzmetov, K. A. Harvey, C. Terry, N. Patel, W. Stillwell, and R. Siddiqui (n-3) Long-Chain Polyunsaturated Fatty Acids Prolong Survival following Myocardial Infarction in Rats J. Nutr., July 1, 2006; 136(7): 1874 - 1878. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Anderson The Fire From Within: The Biggest Ca2+ Channel Erupts and Dribbles Circ. Res., December 9, 2005; 97(12): 1213 - 1215. [Full Text] [PDF] |
||||
![]() |
X. Ai, J. W. Curran, T. R. Shannon, D. M. Bers, and S. M. Pogwizd Ca2+/Calmodulin-Dependent Protein Kinase Modulates Cardiac Ryanodine Receptor Phosphorylation and Sarcoplasmic Reticulum Ca2+ Leak in Heart Failure Circ. Res., December 9, 2005; 97(12): 1314 - 1322. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Zhang and J. H. Brown Role of Ca2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure Cardiovasc Res, August 15, 2004; 63(3): 476 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wu, J. T. Kimbrough, R. J. Colbran, and M. E. Anderson Calmodulin kinase is functionally targeted to the action potential plateau for regulation of L-type Ca2+ current in rabbit cardiomyocytes J. Physiol., January 1, 2004; 554(1): 145 - 155. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Roden A Surprising New Arrhythmia Mechanism in Heart Failure Circ. Res., October 3, 2003; 93(7): 589 - 591. [Full Text] [PDF] |
||||
![]() |
M. R. Rosen Blunderbuss to Mickey Mouse: The Evolution of Antiarrhythmic Targets Circulation, September 3, 2002; 106(10): 1180 - 1182. [Full Text] [PDF] |
||||
![]() |
Y. Wu, J. Temple, R. Zhang, I. Dzhura, W. Zhang, R. Trimble, D. M. Roden, R. Passier, E. N. Olson, R. J. Colbran, et al. Calmodulin Kinase II and Arrhythmias in a Mouse Model of Cardiac Hypertrophy Circulation, September 3, 2002; 106(10): 1288 - 1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Deschenes, N. Neyroud, D. DiSilvestre, E. Marban, D. T. Yue, and G. F. Tomaselli Isoform-Specific Modulation of Voltage-Gated Na+ Channels by Calmodulin Circ. Res., March 8, 2002; 90 (4): e49 - e57. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Gbadebo, R. W. Trimble, M. S.C. Khoo, J. Temple, D. M. Roden, and M. E. Anderson Calmodulin Inhibitor W-7 Unmasks a Novel Electrocardiographic Parameter That Predicts Initiation of Torsade de Pointes Circulation, February 12, 2002; 105(6): 770 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
Members of the Sicilian Gambit New Approaches to Antiarrhythmic Therapy, Part II: Emerging Therapeutic Applications of the Cell Biology of Cardiac Arrhythmias Circulation, December 11, 2001; 104(24): 2990 - 2994. [Abstract] [Full Text] [PDF] |
||||
![]() |
Members of the Sicilian Gambit New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias Eur. Heart J., December 1, 2001; 22(23): 2148 - 2163. [Abstract] [PDF] |
||||
![]() |
Members of the Sicilian Gambit New approaches to antiarrhythmic therapy: emerging therapeutic applications of the cell biology of cardiac arrhythmias Cardiovasc Res, December 1, 2001; 52(3): 345 - 360. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M RODEN and M. E ANDERSON The pause that refreshes, or does it? Mechanisms in torsades de pointes Heart, September 1, 2000; 84(3): 235 - 237. [Full Text] [PDF] |
||||